Related Experiment Video

Updated: May 7, 2026

ACT1-CUP1 Assays Determine the Substrate-Specific Sensitivities of Spliceosomal Mutants in Budding Yeast
07:31

ACT1-CUP1 Assays Determine the Substrate-Specific Sensitivities of Spliceosomal Mutants in Budding Yeast

Published on: June 30, 2022

Test-firing ammunition for spliceosome inhibition in cancer

Scott M Dehm1

  • 1Author's Affiliation: Masonic Cancer Center and Department of Laboratory Medicine and Pathology, University of Minnesota, Twin Cities.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 8, 2013
PubMed

Insights

E7107, a spliceosome inhibitor targeting SF3b, has completed a first-in-human trial. This study represents a key step in developing RNA splicing modulation for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • E7107 is a pladienolide natural product derivative.
  • It functions as a spliceosome inhibitor, specifically targeting the SF3b subunit of U2 small nuclear ribonucleoprotein (snRNP).
  • Modulating RNA splicing is a potential strategy for cancer therapy.

Purpose of the Study:

  • To report the results of the first-in-human clinical trial of E7107.
  • To assess the translational progress of using RNA splicing modulation in cancer treatment.

Main Methods:

  • A first-in-human clinical trial was conducted.
  • The study involved administering E7107 to participants.

Main Results:

  • The results of the first-in-human trial have been reported.
  • This trial represents a translational step for E7107.

Conclusions:

  • The clinical trial of E7107 has been successfully completed.
  • This marks significant progress toward utilizing RNA splicing modulation for cancer therapy.

More Related Videos

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency08:53

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
In vitro Mutagenesis01:16

In vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.